GlaxoSmithKline plc (GSKN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GlaxoSmithKline plc (GSKN) has a cash flow conversion efficiency ratio of 0.141x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (MX$2.22 Billion ≈ $127.88 Million USD) by net assets (MX$15.75 Billion ≈ $906.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GSKN net asset quality index to measure how much of total assets are equity-financed.
GlaxoSmithKline plc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how GlaxoSmithKline plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of GlaxoSmithKline plc to evaluate the quality of earnings relative to operating cash generation.
GlaxoSmithKline plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GlaxoSmithKline plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Howmet Aerospace Inc
NYSE MKT:HWM
|
0.082x |
|
Bank of Nova Scotia
TO:BNS
|
-0.102x |
|
Canadian Imperial Bank Of Commerce
TO:CM
|
0.246x |
|
DBS GROUP ADR/4 SD 1
F:DEV
|
N/A |
|
Lockheed Martin Corporation
NYSE:LMT
|
0.603x |
|
Delta Electronics (Thailand) Public Company Limited
BK:DELTA
|
0.077x |
|
Sanofi
F:SNW2
|
0.051x |
|
China Shenhua Energy Co
SHG:601088
|
0.054x |
Annual Cash Flow Conversion Efficiency for GlaxoSmithKline plc (2013–2024)
The table below shows the annual cash flow conversion efficiency of GlaxoSmithKline plc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see GSKN market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | MX$13.09 Billion ≈ $753.10 Million |
MX$6.55 Billion ≈ $377.18 Million |
0.501x | +17.00% |
| 2023-12-31 | MX$12.79 Billion ≈ $736.36 Million |
MX$5.48 Billion ≈ $315.20 Million |
0.428x | -41.62% |
| 2022-12-31 | MX$10.10 Billion ≈ $581.03 Million |
MX$7.40 Billion ≈ $426.04 Million |
0.733x | +96.80% |
| 2021-12-31 | MX$21.34 Billion ≈ $1.23 Billion |
MX$7.95 Billion ≈ $457.64 Million |
0.373x | -8.15% |
| 2020-12-31 | MX$20.81 Billion ≈ $1.20 Billion |
MX$8.44 Billion ≈ $485.78 Million |
0.406x | -7.15% |
| 2019-12-31 | MX$18.36 Billion ≈ $1.06 Billion |
MX$8.02 Billion ≈ $461.55 Million |
0.437x | -80.95% |
| 2018-12-31 | MX$3.67 Billion ≈ $211.32 Million |
MX$8.42 Billion ≈ $484.63 Million |
2.293x | +15.66% |
| 2017-12-31 | MX$3.49 Billion ≈ $200.79 Million |
MX$6.92 Billion ≈ $398.13 Million |
1.983x | +51.46% |
| 2016-12-31 | MX$4.96 Billion ≈ $285.62 Million |
MX$6.50 Billion ≈ $373.90 Million |
1.309x | +352.40% |
| 2015-12-31 | MX$8.88 Billion ≈ $510.93 Million |
MX$2.57 Billion ≈ $147.85 Million |
0.289x | -72.41% |
| 2014-12-31 | MX$4.94 Billion ≈ $284.07 Million |
MX$5.18 Billion ≈ $297.88 Million |
1.049x | +13.43% |
| 2013-12-31 | MX$7.81 Billion ≈ $449.58 Million |
MX$7.22 Billion ≈ $415.63 Million |
0.924x | -- |
About GlaxoSmithKline plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more